01/27/2015 - 12:01pm

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

01/27/2015 - 11:11am

Health and Human Services Secretary Sylvia Burwell announced goals and a timeline to move the Medicare program toward paying providers based on the quality of care they give patients.

 

01/27/2015 - 11:09am

Teva Pharmaceutical Industries announced that the Food and Drug Administration approved the company’s first generic Nexium delayed-release tablets in the United States.

01/27/2015 - 10:34am

The Food and Drug Administration on Monday announced approval for the first generic version of Nexium (esomeprazole magnesium delayed-release capsules), which are used to treat gastroesophageal reflux disease in adults and children ages 1 year and older.

01/22/2015 - 1:15pm

Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.

 

01/21/2015 - 12:50pm

With specialty and biotech drugs claiming an ever-greater share of the pharmaceutical market and spawning a backlash from payers and patients over their high price tags, pharmacy operators are smack in the middle of a growing tug of war between the drug industry, the public and private health plans struggling to keep up with the new drug-cost paradigm.

01/20/2015 - 6:00pm

The Generic Pharmaceutical Association announced Tuesday that Ralph Neas, president and CEO, would be stepping down from his position in the fall of 2015.

01/20/2015 - 12:44pm

Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.

01/20/2015 - 11:30am

Spurred by market opportunities, short-term market exclusivity for some newly launched single-source generics and rising costs for manufacturing, quality control and raw materials, me-too drug manufacturers have escalated a series of price hikes, some of them significant.